These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 20806117

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
    Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U.
    Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
    [Abstract] [Full Text] [Related]

  • 26. Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery.
    Parolari A, Colli S, Mussoni L, Eligini S, Naliato M, Wang X, Gandini S, Tremoli E, Biglioli P, Alamanni F.
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):336-43. PubMed ID: 12579103
    [Abstract] [Full Text] [Related]

  • 27. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
    Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J, SEPIA-PCI Trial Investigators.
    Circulation; 2007 May 22; 115(20):2642-51. PubMed ID: 17502577
    [Abstract] [Full Text] [Related]

  • 28. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ.
    Drug Metab Dispos; 2009 Aug 22; 37(8):1738-48. PubMed ID: 19420130
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
    Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR.
    J Enzyme Inhib Med Chem; 2011 Aug 22; 26(4):514-26. PubMed ID: 21171894
    [Abstract] [Full Text] [Related]

  • 31. Apixaban: an oral direct factor-xa inhibitor.
    Jiménez D, Yusen RD, Ramacciotti E.
    Adv Ther; 2012 Mar 22; 29(3):187-201. PubMed ID: 22354465
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
    Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, Sun X, Tian H, Plotnikov AN, Burton P.
    J Heart Lung Transplant; 2011 Feb 22; 30(2):218-26. PubMed ID: 20947383
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.
    Leitner JM, Jilma B, Mayr FB, Cardona F, Spiel AO, Firbas C, Rathgen K, Stähle H, Schühly U, Graefe-Mody EU.
    Clin Pharmacol Ther; 2007 Jun 22; 81(6):858-66. PubMed ID: 17410124
    [Abstract] [Full Text] [Related]

  • 35. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
    Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, LaCreta F, Hiraoka M.
    Int J Clin Pharmacol Ther; 2014 Jul 22; 52(7):564-73. PubMed ID: 24725442
    [Abstract] [Full Text] [Related]

  • 36. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
    Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH.
    J Thromb Thrombolysis; 2011 Aug 22; 32(2):183-7. PubMed ID: 21516308
    [Abstract] [Full Text] [Related]

  • 37. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK, Mestries JC, Gascon MP, Ythier A.
    Thromb Haemost; 1997 May 22; 77(5):905-10. PubMed ID: 9184401
    [Abstract] [Full Text] [Related]

  • 38. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep 22; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

  • 39. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C, Pannier A, McIntyre C, Zandt H, Ciorciaro C, Winters K, Pepper T.
    J Clin Pharmacol; 2012 Apr 22; 52(4):499-510. PubMed ID: 21566199
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.